Viewpoint highlights a new selective covalent FGFR3 inhibitor, aiming to reduce toxicity and resistance in FGFR3-altered cancers.
Pan-FGFR inhibitors face toxicity and acquired resistance in FGFR3-altered cancers. This Viewpoint highlights the first covalent FGFR3-selective inhibitor, a promising agent addressing isoform selectivity and clinically acquired resistance in targeted therapy.
No takes yet. Share an insight, caveat, or question.
Guan Wang (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: